Cel-Sci Corporation

Cel-Sci Corporation is a biotechnology company focused on developing innovative immune-related therapies. The company’s foremost project, Multikine, is an investigational immunotherapy designed to harness and enhance the natural defense mechanisms of the immune system to combat cancer. Multikine is primarily targeted towards treating patients with head and neck cancer, a critical area of oncology with high unmet medical needs. With ongoing clinical trials, Cel-Sci Corporation aims to establish a new paradigm in cancer treatment through early intervention before standard treatments like surgery or radiation. Headquartered in Vienna, Virginia, Cel-Sci Corporation collaborates with scientific and medical professionals globally to advance its research pipeline. By leveraging immune system modulation, the company's efforts potentially have wide-reaching implications across various sectors of the healthcare industry, particularly in improving patient outcomes in oncology through novel therapeutic approaches. As part of the biotech sector, Cel-Sci plays a significant role in the dynamic and crucial field of medical innovation, pushing boundaries to address complex health challenges with cutting-edge biotechnology advancements.